scholarly journals The Impact of New-Onset Diabetes Mellitus and Hypertension on All-Cause Mortality in an Apparently Healthy Population: A Ten-Year Follow-Up Study

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Suranut Charoensri ◽  
Kittrawee Kritmetapak ◽  
Tassanapong Tangpattanasiri ◽  
Chatlert Pongchaiyakul
Keyword(s):  
Diabetes Mellitus ◽  
Tertiary Care ◽  
Healthy Population ◽  
Risk Of Death ◽  
Onset Diabetes ◽  
All Cause Mortality ◽  
The Impact ◽  
New Onset Diabetes Mellitus ◽  
New Onset ◽  
Apparently Healthy

Introduction. The comparative effect of new-onset diabetes mellitus (DM) and hypertension (HT) on long-term mortality is a matter of debate. Materials and Methods. From 2007 to 2017, a 10-year longitudinal retrospective cohort study was conducted in Thailand’s tertiary care setting. As baseline data, health check-up data from apparently healthy participants without underlying disease from 2007 were extracted. The vital status of all participants was determined in 2017, ten years after an initial examination. The impact of new-onset DM and HT at baseline on 10-year all-cause mortality was investigated using multivariable logistic regression analysis. Results. The prevalence of new-onset DM and HT was 6.4% and 28.8%, respectively, at baseline. Newly diagnosed diabetes increased the risk of all-cause mortality over 10 years (adjusted OR 4.77 and 95% CI 2.23-9.99). HT, on the other hand, did not increase the risk of death (adjusted OR 1.24 and 95% CI 0.65-2.35). Different HT and DM status combinations were compared to a nondiabetic, nonhypertensive reference. Individuals who were diabetic and hypertensive had a greater risk of death (adjusted OR 6.22 and 95% CI 2.22-17.00). Having DM without HT also increased the risk of death (adjusted OR 4.36 and 95% CI 1.35-12.87). However, having HT without DM did not result in a significant increase in 10-year mortality risk (adjusted OR 1.21 and 95% CI 0.57-2.56). Conclusion. In an apparently healthy population, new-onset DM is more strongly associated with 10-year all-cause mortality than new-onset HT. Having both DM and HT was associated with a greater risk of death when compared to having DM or HT alone.

Abstract 15098: New-Onset Diabetes Mellitus Risk in Statin Users Depends on Baseline HemoglobinA1c Value - Results of VA Database Analysis

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Anna P Ziganshina ◽  
Darren Gemoets ◽  
Laurence Kaminsky ◽  
Aidar R Gosmanov
Keyword(s):  
Diabetes Mellitus ◽  
Mortality Rate ◽  
Statin Therapy ◽  
Baseline Hba1c ◽  
Onset Diabetes ◽  
All Cause Mortality ◽  
Us Veterans ◽  
New Onset Diabetes Mellitus ◽  
Statin Use ◽  
New Onset

Introduction: Statin use in non-diabetic patients is associated with an increased risk of development of new-onset diabetes mellitus (NODM). However, little is known if baseline hemoglobin A1c (HbA1c) can affect diabetogenic risks and mortality benefits of statin therapy. Methods: In a retrospective cohort study between 01/2011 and 12/2018 we collected the data of 152358 non-diabetic US veterans on statin and not on statin therapy who had available baseline HbA1c value and full demographic and clinical information prior to DM diagnosis. The risk of statin-induced DM and all-cause mortality rate were assessed in the whole cohort and based on baseline HbA1c categories: ≤5.6%, 5.7-5.9% and 6.0-6.4%. DM rate and mortality rate were calculated by Cox proportional hazards model adjusted for case-mix. Results: After mean follow up of 6.89 (SD 2.26) years in non-statin users and 3.85 (SD 2.29) years in statin users and adjustments for multiple covariates such as age, gender, ethnicity, obesity, hypertension (HTN), cardiovascular disease, and metformin use, we found that the rate of statin-induced DM depends on baseline HbA1c (Table 1). Analysis by HbA1c categories showed that NODM rate is inversely related to HbA1c level, while statin use in patients with HbA1c 6.0-6.4% was not associated with increased rate of NODM. We did not observe increase in all-cause mortality in statin users and statin users with HTN across HbA1c categories. Atorvastatin use was associated with decrease in all-cause mortality in HTN patients (Table 1). Conclusions: The results of this largest to date analysis of non-diabetic US veterans closely matched for baseline characteristics suggest that the rate of statin-induced DM depends on baseline HbA1c. The significant increase in NODM rate is only observed in patients with baseline HbA1c <6.0% regardless of statin type prescribed. The increased NODM risk is not associated with all-cause mortality in statin users in general including patients with HTN.

1689-P: Perioperative Hyperglycemia around Renal Transplantation Surgery and the Development of New-Onset Diabetes Mellitus after Transplantation

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1689-P
Author(s):  
MARÍA LETICIA MÉNDEZ FERREIRA ◽  
ELVIO D. BUENO ◽  
ALDO BENITEZ ◽  
CONCEPCION M. PALACIOS ◽  
JORGE T. JIMENEZ ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Renal Transplantation ◽  
Transplantation Surgery ◽  
Onset Diabetes ◽  
New Onset Diabetes Mellitus ◽  
New Onset

scholarly journals Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25)

2020 ◽  
Vol 73 (3) ◽  
pp. 740-741
Author(s):  
Javier Ampuero ◽  
Rocío Aller ◽  
Rocío Gallego-Durán ◽  
Javier Crespo ◽  
José Luis Calleja ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Arterial Hypertension ◽  
Significant Fibrosis ◽  
Onset Diabetes ◽  
New Onset Diabetes Mellitus ◽  
New Onset

scholarly journals New-onset Diabetes Mellitus Following Successful Kidney Transplantation Facilitates Aortic Stiffening

2019 ◽  
Vol 51 (4) ◽  
pp. 1239-1243 ◽  
Author(s):  
Bernadett Borda ◽  
György Lázár ◽  
Árpád Kormányos ◽  
Péter Domsik ◽  
Anita Kalapos ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Kidney Transplantation ◽  
Onset Diabetes ◽  
Aortic Stiffening ◽  
New Onset Diabetes Mellitus ◽  
New Onset
Sign in / Sign up

Export Citation Format

Share Document